Telsar Pharma's Series A Round

Telsar Pharma raised a round of funding on April 26, 2012.

Telsar Pharma is a virtual company created to develop and commercialize ASP3291, a melanocortin receptor antagonist for the potential treatment of ulcerative colitis. The compound pipeline originated …

Articles about Telsar Pharma's Series A Round: